Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in the context of pcos in this controlled clinical trial publication.

The objective of the present study was to investigate the response patterns of insulin-like growth factors (IGFs) and interleukin-6 (IL-6) to ovarian stimulation within 24 h in patients with polycystic ovary syndrome (PCOS) in comparison with normally ovulating women.

Why It Was Studied

This controlled prospective clinical study involved 60 women who attended an infertility clinic.

For the induction of the ovarian stimulation, fifty-two patients with PCOS and eight control cases were injected with human menopause gonadotropin (hMG) and human chorionic gonadotropin (hCG) during the early follicular phase of the natural or induced menstrual cycle.

Who Took Part

The study group was 24 patients.

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

Serum levels of estradiol (E2), IGF-I, IGF-II and IL-6 were measured by radioimmunoassay.

What Was Measured

The subject headings attached to it are Chorionic Gonadotropin, Estradiol, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Interleukin-6, Menotropins and Ovulation Induction.

What This Means in Plain Language

This is a controlled clinical trial of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in 24 patients in people with pcos.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2009 (Systems biology in reproductive medicine), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page and the HMG (Human Menopausal Gonadotropin) compound page, PCOS research.